Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11419
Shown on this page
12
Current sort
Recently updated
Location scope
Seattle, WA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Seattle, Washington. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 817–828 of 11,419 matching trials in Seattle, WA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional Results available

ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent

NCT03130777
Conditions
Pulmonary Disease, Transcatheter Pulmonary Valve Replacement (TPVR), Tetralogy of Fallot, Congenital Heart Disease, Pulmonary Regurgitation
Interventions
Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Conditions
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
Interventions
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Phase 3 Interventional Results available

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790
Conditions
Polycythemia Vera
Interventions
Rusfertide, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
80
States / cities
Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more
Conditions
Ovarian Cancer
Interventions
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Genetic · Combination Product
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Augusta, Georgia + 6 more
Conditions
Severe Aplastic Anemia
Interventions
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Drug · Procedure · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Jaguar LAA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
659
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Conditions
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
453
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
Conditions
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy, Partial Hepatectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
367
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 253 more
Conditions
Breast Screening
Interventions
Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
45 Years to 74 Years · Female only
Enrollment
108,508 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more